Format

Send to

Choose Destination
Nat Biotechnol. 2014 Sep;32(9):874-6. doi: 10.1038/nbt.3003.

The special case of gene therapy pricing.

Author information

1
CVS Caremark, Woonsocket, Rhode Island, USA.
2
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

Abstract

Gene therapy companies that pursue high, one-time payments for their products risk a backlash from payors. A better solution may lie in a pay-for-performance model.

Comment in

PMID:
25203033
DOI:
10.1038/nbt.3003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center